Jesús Martín

发表

Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.

J. Sierra, J. Besalduch, J. Pérez-Simón, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic factors of chronic graft-versus-host disease following allogeneic peripheral blood stem cell transplantation: the national institutes health scale plus the type of onset can predict survival rates and the duration of immunosuppressive therapy.

E. Colado, F. Sánchez-Guijo, J. S. San Miguel, 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Minimal residual disease monitoring and immune profiling using second generation flow cytometry in elderly multiple myeloma Running head: 2 generation flow MRD monitoring in elderly MM

A. Órfão, N. Puig, J. Flores-Montero, 2018 .

Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients.

A. Órfão, J. V. van Dongen, N. Puig, 2016, Blood.

Liver function tests and absolute lymphocyte count at day +100 are predictive factors for extensive and severe chronic graft‐versus‐host disease after allogeneic peripheral blood stem cell transplant

E. Colado, F. Sánchez-Guijo, J. S. San Miguel, 2010, American journal of hematology.

Immunogenomic identification and characterization of granulocytic myeloid derived suppressor cells in multiple myeloma.

David Lara-Astiaso, F. Prósper, A. Órfão, 2020, Blood.

Curative Strategy (GEM-CESAR) for High-Risk Smoldering Myeloma (SMM): Carfilzomib, Lenalidomide and Dexamethasone (KRd) As Induction Followed By HDT-ASCT, Consolidation with Krd and Maintenance with Rd

N. Puig, M. Calasanz, A. Oriol, 2018, Blood.

Predicting long-term disease control in transplant-ineligible patients with multiple myeloma: impact of an MGUS-like signature

N. Puig, A. Oriol, N. Gutiérrez, 2019, Blood Cancer Journal.

Measurable Residual Disease by Next-Generation Flow Cytometry in Multiple Myeloma.

A. Órfão, J. V. van Dongen, N. Puig, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Response to Novel Drugs before and after Allogeneic Stem Cell Transplantation in Patients with Relapsed Multiple Myeloma.

E. Ocio, J. S. San Miguel, J. Pérez-Simón, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Role of urine immunofixation in the complete response assessment of MM patients other than light-chain-only disease.

N. Puig, A. Oriol, B. Paiva, 2019, Blood.

Intermediate doses of cytarabine plus granulocyte–colony‐stimulating factor as an effective and safe regimen for hematopoietic stem cell collection in lymphoma patients with prior mobilization failure

J. Pérez-Simón, I. Espigado, J. Falantes, 2015, Transfusion.

Circulating Tumor Cells for the Staging of Patients With Newly Diagnosed Transplant-Eligible Multiple Myeloma

A. Órfão, N. Puig, J. Flores-Montero, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Sleep‐Disordered Breathing Is Independently Associated With Increased Aggressiveness of Cutaneous Melanoma: A Multicenter Observational Study in 443 Patients

A. Martorell, R. Farré, D. Gozal, 2018, Chest.